Resveratrol and toxin-induced senescence in primary human and pig liver cells
In this abstract, brief exposure to a liver-derived toxic metabolite cocktail triggered senescence in primary human and porcine hepatocytes, with loss of albumin and urea production; 5 µM resveratrol reversed this in a species- and function-dependent way. [1]
Automatic summary · not editorially reviewed
The key findings
Brief exposure of HepG2 cells in vitro to a liver-derived toxic metabolite cocktail triggered a senescence state called SILT. [1]
In primary human and porcine hepatocytes, SILT was accompanied by loss of albumin and urea production and was reversible by 5 µM resveratrol in a species- and function-dependent manner. [1]
Gene Set Enrichment Analysis indicated SILT in vivo in datasets from diseased, but not healthy, liver. [1]
The source at a glance
- Study type / format
- In vitro cell study with analysis of reference transcriptomic datasets (abstract).
- Population / context
- HepG2 cells and primary human and porcine hepatocytes in vitro, plus reference transcriptomic datasets from diseased and healthy liver.
- Summary based on
- Study abstract
- Original publication
- October 6, 2026
Senescence triggered in primary liver cells by toxins
The abstract describes a state called senescence induced by liver toxins (SILT). Brief exposure of HepG2 cells in vitro to a liver-derived toxic metabolite cocktail triggered it. SILT combined loss of proliferative capacity, proinflammatory changes, senescence-associated β-galactosidase reactivity and upregulation of cyclin dependent kinase inhibitors with a broader loss of essential hepatocyte functions. The authors then extended the analysis to primary hepatocytes: both human and porcine liver cells underwent SILT in vitro when exposed to concentrations of endogenous toxins typical of liver disease.
Supporting source [1]
Albumin and urea loss, resveratrol reversal in vitro
As in HepG2 cells, SILT in primary hepatocytes was accompanied by loss of albumin production, measured by ELISA, and of urea synthesis, measured biochemically. This loss was reversible by 5 µM resveratrol in a species- and function-dependent manner. Deeper transcriptomic profiling of SILT revealed activation of stress and inflammatory pathways combined with repression of hepatocyte metabolic programmes. These are in vitro cell findings; the abstract does not report human outcomes or a clinical trial.
Supporting source [1]
SILT signature in diseased, not healthy, liver datasets
A Gene Set Enrichment Analysis indicated that SILT is present in vivo in multiple reference transcriptomic datasets derived from diseased, but not healthy, liver. The authors say this is consistent with a population of SILT hepatocytes among the senescent cells found in the ageing organ in vivo. They suggest SILT may contribute to the ultimate failure of liver function, which may potentially be delayed by resveratrol treatment. These are proposed possibilities, not demonstrated causal or clinical effects.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from cells in vitro and from analysis of existing transcriptomic datasets. The abstract reports no human outcomes or clinical trial, and the possible delay of liver failure by resveratrol is a suggestion, not a demonstrated effect.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Hedari N, Hesketh A, Sandeman S, Davies NA, Baker N, Faragher RGA. · europepmc.org · October 6, 2026